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Abstract
This brief review emphasises the importance of proper diagnosis before management of patients with pituitary lesions. 
Surgery remains the treatment of choice for many pituitary adenomas but not all of them require surgery. Lactotroph 
adenomas secreting an excessive amount of prolactin (often termed as prolactinomas) are usually responsive to 
pharmacological treatment with dopamine receptor (D2) agonists and should not be treated surgically except in 
a selected group of patients. Surgery is no longer the first-line treatment for prolactinomas. All those patients of 
prolactinomas who may be considered for surgery must be discussed in a multidisciplinary team meeting before 
surgical intervention. In clinical practice in Pakistan, one comes across a noticeable number of patients of lactotroph 
adenomas referred after surgical resection performed as a primary treatment for their pituitary adenomas. Most of 
these patients were referred to the endocrinology department following a recurrence of prolactinomas, and further, 
surgical resection could not be performed. There are no local data of those prolactinomas which may have been cured 
after surgery. The comparison between surgical and pharmacological treatment is not possible in local population but 
worldwide data available in literature suggests that surgery should no longer be the first-line treatment in the majority 
of patients with prolactinomas. Pharmacological treatment is convenient, more effective and longer lasting compared 
to surgical treatment.
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Introduction
This brief review is aimed at reviewing basic aspects 
of the management of prolactinomas for health-care 
professionals of all specialities and grades. There seems 
to be a lack of awareness about prolactinomas not only 
amongst patients but also amongst some of the health-
care professionals in Pakistan. Most patients present 
late to a doctor, but even after the presentation, they are 
not referred to an appropriate centre immediately. Lack 
of availability of the appropriate laboratory facilities in 
most of the hospitals further emphasises the importance 
of timely referral to appropriate centres for investigation 
and management of these patients. Furthermore, many 
of these patients may not present to general practitioners 
but may present to gynaecologists (with amenorrhoea) 
and ophthalmologists (visual field defects). In essence 
a multidisciplinary approach is required for the best 
management of such patients.
Prolactin is a single chain polypeptide hormone of 
198 amino acids and approximately 24,200 D.[1] It is 
produced and secreted by the acidophilic cells of the 
anterior pituitary gland. Most of the anterior pituitary 
gland hormones secretion is regulated by stimulatory 
and inhibitory effects of hypothalamic hormones. 
Prolactin production and secretion by lactotroph cells 
are inhibited by dopamine produced in the hypothalamus 
and released in hypophyseal-hypothalamic circulation. 
All the stimulating factors for prolactin are not fully 
understood, but thyrotropin-releasing hormone produced 
in the hypothalamus is one of the prolactin stimulatory 
agents. This explains the reason for high prolactin level in 
some patients of primary hypothyroidism. Lactation has 
almost always been considered as its main function, and 
the hormone has been named accordingly,[2] but this is not 
JOURNAL OF CANCER & ALLIED SPECIALTIES 2
REVIEW ARTICLE J Cancer Allied Spec 2017;3(1):2
the only functions it performs in mammary glands. It has 
a trophic effect on the secretory epithelial tissue of the 
mammary glands. This trophic effect results in growth and 
prepares the tissue for the initiation of lactation. Prolactin 
not only helps in the initiation of lactation but also then 
maintains it as well.
Since almost all the vertebrates produce prolactin, most 
of the functions of prolactin have been studied in animal 
models. In addition to its function in reproduction 
and lactation, it has also been associated with a role 
in metabolism, behaviour, thermoregulation and 
osmoregulation. Up to 300 different biological actions 
of prolactin have been described in vertebrates.[3] It is 
important to manage abnormalities of such an important 
hormone properly.
Presentation
Prolact inoma is  one of  the  many causes  of 
hyperprolactinemia.[4] Hyperprolactinemia could be 
physiological (during lactation and pregnancy) or 
pathological which should be investigated and treated. 
Hyperprolactinemia can also be transient due to a number 
of reasons, but clinical symptoms of hyperprolactinemia 
develop if it remains persistently high. Most patients with 
prolactinomas usually present with symptoms and signs of 
hyperprolactinemia or compression of pituitary tumour on 
the surrounding intracranial structures. Hyperprolactinemia 
reduces gonadotropin levels and patients often present with 
clinical and biochemical features of hypogonadotropic 
hypogonadism. In a retrospective study conducted by Peng 
et al. found that most adult men experience growth hormone 
deficiency and hypogonadism with prolactinomas.[5] 
Most of these patients are young; however, older patients 
may also present with prolactinomas. Fernandez et al. 
conducted a study in 81,449 inhabitants of Banbury, 
Oxfordshire and in the United Kingdom and determined 
the incidence of pituitary adenomas there to be 77.6 cases 
per 100,000 population, with the majority of cases (57%, or 
44.4 persons per 100,000 population) being prolactinomas.
In this particular population, the incidence of prolactinomas 
was 75% of all pituitary adenomas occurring in individuals 
up to the age of 20 years and 61% of all the pituitary 
adenomas in individuals between the ages of 20 years 
and 60 years.
The incidence of prolactinomas was higher amongst 
women compared to men as prolactinomas made 76% 
of all the pituitary adenomas in women while in men 
57% were non-functioning adenomas.[6] Carter et al. 
found that 60% of men present with macroprolactinomas 
and 90% of women present with microprolactinomas.[7] 
Women present early with menstrual irregularities. It can 
present with oligomenorrohea, amenorrohea or irregular 
menstrual bleeding.[8] Patients can sometimes present 
with secondary amenorrohea or primary amenorrohea. 
Hyperprolactinemia is often detected during work up 
in infertility clinics.[8] Women may also experience 
vaginal dryness, dyspareunia and bone mineral density 
(BMD) loss secondary to hypoestrogenemia secondary 
to hypogonadotropic hypogonadism.[4] Men with 
prolactinomas usually present late. They present with 
either compression effects on surrounding structures 
or deficiency of other pituitary hormones. Since 
hypogonadotropic hypogonadism develops gradually over 
time, most patients may not notice this until the symptoms 
are fairly advanced. Many such patients present for the 
1st time with visual field defects due to compression of 
tumour on optic chiasm.
Large tumours may affect other surrounding structures 
in the vicinity including III, IV and VI cranial nerves. 
Many patients present with headache with large tumours 
stretching onto to pain sensitive surrounding structures. 
Men could present with erectile dysfunction, low libido, 
loss of BMD and infertility.[7] Galactorrohea remains the 
other most commonly experienced symptom amongst 
such patients. Approximately 30–60% patients experience 
this symptom with hyperprolactinemia. Gynaecomastia 
is not a typical sign in such patients although it has 
been reported to be associated with some patients of 
hyperprolactinemia. Pre-pubertal hyperprolactinemia 
can result in female body habitus in male patients due to 
hypogonadotrophic hypogonadism. Incidental detection 
of pituitary adenomas has increased in recent years 
with an increased number of computed tomography and 
magnetic resonance imaging (MRI) scans. Prolactinomas 
constitute a reasonable proportion of these incidentally 
detected pituitary adenomas. Larger adenomas can cause 
a deficiency of other pituitary hormones in addition to 
gonadotropins. Cortisol and thyroxin must be replaced 
once their deficiency is confirmed. Cortisol has to 
be replaced before thyroxin replacement to avoid an 
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adrenal crisis. Prolactinomas can also present along 
with other endocrine neoplasias termed as multiple 
endocrine neoplasia (MEN). Prolactinomas associated 
with parathyroid and pancreatic tumours are termed as 
MEN Type 1. Such patients usually present early in their 
lives with symptoms of one or more hormones excess; 
parathyroid in 90%, prolactin in 66% and gut hormones 
excess in 50% patients. In younger patients, it is advisable 
to assess other hormones (pituitary, gut hormones and 
parathyroid) once an adenoma is detected in pancreas, 
pituitary or parathyroid glands.
Laboratory Assessment
Most laboratories use immunoassay as the first line 
investigation for prolactin level assessment. Prolactin 
immunoassay is more like antigen-antibody reaction. 
Prolactin molecule in sample acts as antigen while anti-
prolactin antibodies in assay attach to prolactin. One 
prolactin molecule is sandwiched between two antibodies. 
This suggests that laboratory assay should have more 
antibodies than antigen to reliably detect prolactin 
concentration in a given blood sample. If the antigen 
concentration increases significantly, the laboratory 
assay antibodies may not be able to sandwich prolactin 
molecules properly.[9,10] In this situation, a significant 
proportion of prolactin is attached to only one antibody 
and is not detected. This leaves fewer antibodies in the 
assay to be attached on two antigen sites (sandwich 
prolactin molecule) of prolactin and be detected. This 
will result in a falsely low detectable prolactin level 
in a given blood sample. This is called ‘hook effect’ 
when very high levels of prolactin in a blood sample 
result in a falsely low detectable prolactin and hook the 
result in the wrong direction. One could overcome this 
phenomenon by either reducing the concentration of 
antigen or increasing concentration of antibody. One way 
of reducing antigen concentration would be to dilute the 
blood sample. Normally with dilution, you would expect 
the detectable prolactin levels to drop; however, with hook 
effect sample the prolactin levels will be higher in diluted 
sample. The dilution of the blood sample is continued to 
be increased in a stepwise manner as long as the prolactin 
level continues to rise with increasing sample dilution. 
Once the prolactin level starts to drop with increasing 
dilution further dilutions are not necessary. The corrected 
level of prolactin is then documented by multiplying it 
with the number of times the blood sample was diluted. 
The immunoradiometric PRL assay must be performed 
with serum dilution to overcome the high-dose PRL hook 
effect in all new patients with pituitary macroadenomas 
who may have a prolactinoma.[11] Dilution of sample is 
especially recommended when there is a discrepancy 
between pituitary tumour size and prolactin levels. The 
hook effect was first described in 1992[12] and Comtois 
et al.[13] reported the first patient in whom the hook effect 
lead to misdiagnosis of a large macroprolactinoma. 
Subsequently, a good number of cases was reported in 
literature with hook effect. It is important to recognise 
this phenomenon for correct diagnosis and treatment of 
pituitary tumours.
Most laboratories usually assess total prolactin as the 
initial investigation in all patients. Once the immunoassay 
detects high prolactin level further workup is required to 
assess if the prolactin is biologically active. Assessment 
of bio-active (monomeric) prolactin is the laboratory 
investigation of choice in patients with clinical features 
of hyperprolactinemia and/or pituitary tumour. Most of 
human circulating prolactin exists in a monomeric form of 
23 kDa (85–90%). A proportion of prolactin circulates as 
high molecular mass isoforms including big-PRL, a dimer 
of 50 kDa and big–big-PRL or macroprolactin, a variant 
of 150–170 kDa.[14] It is believed that macroprolactin 
is formed when prolactin binds to a protein IgG 
(immunoglobulin G) in circulation. This IgG-prolactin 
complex becomes bigger in size and becomes biologically 
inactive although stays in circulation for longer than 
monomeric prolactin. Posttranslational modification 
of pituitary prolactin with varying glycosylation and 
phosphorylation degrees has also been suggested as a 
possible cause of macroprolactin.[15,16] Macroprolactin 
usually does not cause clinical symptoms and does 
not require any treatment. There are only a few case 
reports suggesting clinical symptoms with high levels 
of macroprolactin, but an overwhelming majority of 
patients with macroprolactin are asymptomatic and do not 
require treatment. The exact mechanism of inactivity of 
macroprolactin is not known, but the most widely believed 
theory is about the size of IgG-prolactin complex. IgG-
prolactin complex becomes too big to cross the vessel wall 
and not released into tissues to produce any biological 
effects. Prolactin part of prolactin-IgG complex maintains 
its immunoreactivity and is detected during laboratory 
JOURNAL OF CANCER & ALLIED SPECIALTIES 4
REVIEW ARTICLE J Cancer Allied Spec 2017;3(1):2
assays. The gold standard test to determine the presence of 
macroprolactinemia is gel filtration chromatography, but 
more available and less expensive alternatives have been 
described, like precipitation with polyethylene glycol.[17]
In addition to prolactin other hormones of anterior 
pituitary gland should be assessed regardless of prolactin 
level. This should include lutenizing hormone, follicle-
stimulating hormone, testosterone (for men), estradiol (for 
women), cortisol with or without adrenocorticotrophic 
hormone, insulin-like growth factor 1 (IGF-1), thyroid-
stimulating hormone and free thyroxin 4. Certain pituitary 
adenomas can co-secrete hormone, especially growth 
hormone and prolactin. All patients with high prolactin 
level should have their IGF-1 level assessed to look for 
this possibility of co-secretion.
Treatment
Once the diagnosis is confirmed treatment is planned 
according to biochemical and radiological findings. 
Prolactinomas are divided into two main sub-types based 
on their size: Microprolactinoma (tumour <1 cm in size 
on radiologic imaging) and macroprolactinoma (tumour 
over 1 cm in size). This size based divide helps in planning 
treatment of these adenomas. The exact aetiology of 
micro- and macro-prolactinomas is not known; however, 
microprolactinomas generally do not grow in size to 
become macroprolactinomas in 95% of cases. Hence, 
the treatment is tailored according to tumour size and 
behaviour. One of the following approaches can be used 
to treat prolactinomas:
1. Monitoring without active intervention
2. Pharmacological and surgical intervention
3. Others, for example, radiotherapy.
Monitoring without Intervention
Asymptomatic microprolactinomas with stable prolactin 
levels and no abnormality of any of the other pituitary 
hormones do not always require intervention and 
these prolactinomas can sometimes be monitored 
with prolactin levels and size on pituitary MRI scans. 
Pharmacological treatment will be indicated if prolactin 
level continues to raise, other pituitary hormones 
are affected and/or prolactinoma increases in size. 
Furthermore, some infertility centres recommend 
normalisation of prolactin levels in women before 
in vitro fertilisation treatment cycle to maximize chances 
of ovulation. In the absence of any of these conditions 
radiological and biochemical monitoring is advised 
on 3–6 monthly intervals. Many patients of polycystic 
ovarian syndrome have high prolactin levels with no 
identifiable adenoma in the pituitary gland. The exact 
mechanism of high prolactin in these patients in not 
known; however, these patients should be monitored for 
symptoms as above and treatment should be offered using 
the same criteria as those who have got prolactinomas. 
Since there is no detectable pituitary adenoma on MRI 
scan, most centres would not recommend repeating scans 
if two scans at least 6 months apart do not show a change 
in the pituitary gland. After initial two scans, another scan 
should be considered if there is a considerable increase 
in prolactin level or there are clinical signs of pituitary 
tumour - visual field loss.
In some cases of hyperprolactinemia no cause can be found. 
In the absence of any other cause of hyperprolactinemia, 
it is believed that the pituitary adenoma may be too 
small to be identified as a separate entity in pituitary 
gland on MRI scans. Monitoring strategy should remain 
the same in these patients with initial two scans at least 
6 months apart and subsequent scans if required. Many 
of the medicines used in the treatment of psychiatric 
conditions can cause hyperprolactinemia.[18] Most of 
these medicines are dopamine antagonists. Patients need 
to take these medicines to help with their psychiatric 
condition. The prolactin released in these conditions 
causes true hyperprolactinemia and can cause clinical 
symptoms of hyperprolactinemia. I would strongly 
recommend for every patient to have their prolactin level 
assessed before the commencement of these medications. 
Psychiatrists should get a baseline prolactin level on all 
these patients and refer to endocrinologists for assessment 
of those patients who have high monomeric prolactin 
level (unpublished; Hanson, P). Most patients will not 
need diagnostic workup for hyperprolactinemia if the 
prolactin level rises after the commencement of dopamine 
antagonists. A sudden significant rise in prolactin level 
or other signs of pituitary adenoma in such patients may 
require investigations for hyperprolactinemia. It is usually 
not possible to discontinue treatment with psychiatric 
medications to assess the effect of these medications on 
prolactin level if baseline prolactin level is not recorded 
before the commencement of these medications. One 
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may consider switching to one of the few medications 
which do not increase prolactin levels; however, this is 
not always possible and may be risky in patients who are 
symptomatically controlled with a specific medication. It 
is generally recommended not to treat such patients with 
dopamine receptor agonists to control prolactin levels, but 
it has been done successfully in some patients to control 
symptoms of hyperprolactinemia with good response.[19]
Hence, many patients with pituitary microprolactinoma 
will not require any active treatment and monitoring alone 
may be sufficient. Women who wish to get pregnant during 
this monitoring can go ahead with pregnancy. Prolactin 
level rises during pregnancy and cannot be monitored 
during pregnancy as there are no agreed pregnancy 
specific values available. Such patients should have visual 
field assessments once every trimester during pregnancy. 
Breastfeeding is not contraindicated in such patients. 
Active intervention is indicated if there is deterioration 
in visual fields during pregnancy. Such patients will 
require individualised care following discussion with 
endocrinologists, neurosurgeons and obstetricians. 
However, the possibility of such a scenario is very low.
Pharmacological Treatment
Pharmacological treatment is indicated in symptomatic 
microprolactinomas,[20] for patients with infertility 
associated with hyperprolactinemia and almost all 
macroprolactinomas. Dopamine receptor agonists are first-
line agents. They are very effective not only in controlling 
growth of tumour but also to reduce tumour size soon 
after their commencement. The dose is usually gradually 
increased but treatment with higher doses for immediate 
response has been reported in literature. Bromocriptine is 
being used for a long time and is relatively easily available 
in Pakistan. It is usually started in a dose of 2.5 mg 3 times 
a day and can be increased at weekly intervals or according 
to patient response to 10–30 mg in a day in divided doses. 
Multiple daily dosing regimen and gastrointestinal side 
effects limit its use in some patients. This is the preferred 
dopamine receptor agonist to be used in pregnant women 
or in women planning to get pregnant. Cabergoline is the 
other dopamine receptor agonist. It is better tolerated 
of the two, lower treatment failure rate, better dosing 
regimen and better patient experience. It is usually started 
at a dose of 250 mcg (half a tablet of 500 mcg) once 
or twice a week. So far, this is not widely available in 
Pakistan. If possible, this should be the first-line dopamine 
receptor agonist used in the treatment of prolactinomas. 
Higher doses of dopamine receptor agonists have been 
associated with cardiac adverse effects in animal studies. 
Monitoring of cardiac functions in patients taking low 
doses of dopamine receptor agonists remains a debatable 
subject. It is suggested to get a baseline echocardiogram 
done on patients before the commencement of therapy 
and subsequently arrange more scans depending on 
clinical condition, dose of cabergoline or at least, once 
a year. Dopamine receptor agonists are used in much 
smaller doses in the treatment of prolactinoma and none 
of the studies have so far conclusively proven adverse 
cardiac effect in patients treated for prolactinomas with 
dopamine receptor agonists. Quinagolide is a non-ergot 
dopamine receptor (D2) agonist which can be used as a 
second-line agent if bromocriptine or cabergoline cannot 
be used. The availability of this agent remains an issue 
in Pakistan. The response is assessed by reduction in 
prolactin levels and is confirmed by repeat MRI pituitary 
scan in 3–6 months. It is very unlikely that there will 
be a reduction in tumour size if the prolactin level does 
not reduce with medications. In some patients, prolactin 
level may not drop to normal range. This is especially 
found with very high baseline prolactin levels. Most of 
these patients will become symptoms free with reduction 
in tumour size despite marginally high prolactin levels. 
These patients are not considered as treatment failure; 
however, if the prolactin level does not drop at all or it 
starts to persistently rise again following initial drop, such 
patients are classed as treatment failure. Cabergoline has 
the least of the treatment failure rate. It ranges from 10% 
to 13 % in different studies.
Surgical Treatment
Surgery is neither the first-line treatment nor the treatment 
of choice for almost all prolactinomas. The success rate 
for microprolactinomas is 70–75%, but there always 
remains a possibility of affecting other pituitary hormones 
during surgery in addition to other possible complications 
potentially associated with a major neurosurgical 
procedure. In Pakistan, a significant proportion of patients 
with macroprolactinomas undergo surgery as the primary 
treatment. The cure rate falls to only 30–35% in cases of 
macroprolactinomas. Assessment of prolactin level for all 
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pituitary lesions remains key to diagnosis of prolactinomas 
and all such cases must be referred to appropriate centres 
with endocrinology and neurosurgical expertise.
Health-care professionals in Pakistan need to be 
mindful of the fact that post-surgical deficiency of other 
pituitary hormones on lifelong basis significantly affects 
lives of these patients. Neurosurgeons need to give it 
serious thought before attempting any kind of pituitary 
surgery. We may be able to cure one condition but could 
potentially leave them with a lifelong complication of 
hypopituitarism. Each hormone secreted by pituitary 
gland is essential for normal functioning of an individual. 
Cortisol deficiency is not only associated with significant 
morbidity but also carries mortality if not managed 
properly. Availability of hydrocortisone also remains an 
issue especially outside big cities of the country. Same is 
true for thyroxin in cases of secondary hypothyroidism. 
Not only that growth hormone cost is out of reach for 
most patients in Pakistan the laboratory assessment of the 
hormone but is also only available in a limited number of 
laboratories in the country. Since the majority of patients 
with prolactinomas are young, surgery is indicated in a 
selected group of patients with:
1. Prolactinoma is not responsive to pharmacological 
treatment or those who show the progression of 
disease following initial response to pharmacological 
treatment.
2. Patient cannot or would not take medications.[21,22]
Prolactin level may also be raised in non-functioning 
pituitary tumours compressing the pituitary stalk. 
Hypothalamus is believed to produce inhibitory effects 
on prolactin producing cells in pituitary gland through 
pituitary stalk. Suprasellar tumours or tumours with 
suprasellar extension compress the stalk and can block this 
inhibitory effect, often termed as ‘stalk effect.’ Treatment 
of primary tumour will help control prolactin levels in these 
patients. Prolactin level in these cases is usually not very 
high. Some studies have used prolactin level to differentiate 
between different causes of hyperprolactinemia but none of 
those have been conclusive enough to be used reliably in 
clinical practice. A prolactin level >5.25 IU/L (250 μg/L) 
usually indicates the presence of a prolactinoma and 
a prolactin level >10.5 IU/L (500 μg/L) is considered 
very suggestive of a macroprolactinoma. In some cases 
of macroprolactinomas prolactin levels are even far 
>21.2 IU/L (1000 μg/L). In contrast, marginally elevated 
prolactin levels (usually >2.1 IU/L (100 μg/L) are very 
suggestive of these large tumours as non-secreting 
tumours.[23]
Other Options
Radiotherapy is a last resort for treatment of prolactinomas. 
This should only be considered a treatment option in 
patients who cannot undergo surgery and cannot or would 
not take oral medications for prolactinomas. Success 
rates remain very low with radiotherapy and due to this 
not many well-designed studies have been performed to 
accurately assess the success rate of this treatment option.
Treatment during Pregnancy
Many women attend endocrinology clinic with high 
prolactin levels and menstrual irregularities due to the 
effect of prolactin on their gonadotropins. This could 
affect ovulation and hence fertility. With medical 
treatment, the prolactin usually settles in normal range 
with normalisation of gonadotropin functions. Women 
with microprolactinoma are advised to discontinue their 
medications once pregnancy is confirmed. Medications 
are generally advised to be continued during pregnancy 
in patients with macroprolactinoma. Many clinicians 
would discontinue medications even in patients of 
macroprolactinoma if the tumour is away from optic 
chiasm and other vital structures. Formal visual field 
assessments should be carried out at least once, during 
each trimester. Women can breastfeed after delivery, and 
they are assessed after completion of breastfeeding for 
starting pharmacological therapy again.
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